# Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer

> **NCT04508803** · PHASE2 · COMPLETED · sponsor: **Fudan University** · enrollment: 37 (actual)

## Conditions studied

- Treatment Efficacy

## Interventions

- **DRUG:** HX008，Niraparib
- **DRUG:** HX008，Niraparib
- **DRUG:** HX008，Niraparib，Trastuzumab
- **DRUG:** HX008，Niraparib，Pyrrolitinib

## Key facts

- **NCT ID:** NCT04508803
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-09-14
- **Primary completion:** 2022-08-20
- **Final completion:** 2023-02-28
- **Target enrollment:** 37 (ACTUAL)
- **Last updated:** 2024-09-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04508803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04508803, "Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04508803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*